New developments on the serotonin hypothesis of depression: Shunt of tryptophan;Nuovi sviluppi dell'ipotesi serotoninergica della depressione: Shunt del triptofano

Rivista di Psichiatria

Volumn 48, Issue 1, 2013, Pages 23-34

  Marazziti, Donatella ^a   Baroni, Stefano ^a   Picchetti, Michela ^a   Piccinni, Armando ^a   Silvestri, Stefano ^a   Dell'Osso, Liliana ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Depression; Indoleamine 2,3 dioxygenase (IDO); Kynurenine; Serotonin; Tryptophan; Tryptophan 2,3 dioxygenas (TDO)

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; LIVER ENZYME; SEROTONIN; STRESS HORMONE; TRYPTOPHAN 2,3 DIOXYGENASE; TUMOR NECROSIS FACTOR ALPHA; TRYPTOPHAN;

ARTICLE; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; ENZYME METABOLISM; GENE EXPRESSION; GENETIC PREDISPOSITION; HEREDITY; MAJOR DEPRESSION; UPREGULATION; DEPRESSION; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; NERVOUS SYSTEM DEVELOPMENT; PHYSIOLOGY; REVIEW;

CYTOKINES; DEPRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEUROGENESIS; PITUITARY-ADRENAL SYSTEM; SEROTONIN; TRYPTOPHAN;

MLCS; MLOWN;

EID: 84875585651     PISSN: 00356484     EISSN: 20382502     Source Type: Journal    
DOI: None     Document Type: Article

References (156)

1. Maes M, Meltzer HY. Psychopharmacology, the fourth generation of progress. In: Bloom, Kupfer (ed). New York: Raven Press, 1995.
2. Owens MJ, Nemeroff CB. The serotonin transporter and depression. Depress Anxiety 1998; 8: 5-12.
3. Marazziti D, Dell'Osso L, Rossi A, et al. Decreased platelet [3H]paroxetine binding sites in suicide attempters. Psych Res 2001; 103: 125-31.
4. Kirsch I. Antidepressant drugs "work", but they are not clinically effective. Br J Hosp Med 2008; 69: 359.
5. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO6NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008; 29: 287-91.
6. Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009; 24: 27-53.
7. Zorilla EP, Luborsky L, McKay JR, Roesnthal R, Houldin A. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15: 199-226.
8. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of major depression. Trend Immunol 2006; 27: 24-31.
9. Maes M, Scharpe S, Meltzer HY, Cosyns P. Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression. Biol Psychiatry 1993; 34: 690-701.
10. Maes M, Vandoolaeghe E, Neels H, et al. Serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry 1997; 42: 349-58.
11. Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007; 55: 453-62.
12. Simen BB, Duman CH, Simen AA, Duman RS. TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 2006; 59: 775-85.
13. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
14. Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969; 1: 32-9.
15. Rubin RT, Mandell AJ, Crandall PH. Corticosteroid responses to limbic stimulation in man: Localization of stimulus sites. Science 1966; 153: 767-68.
16. Lapin IP. Convulsions and tremor in immature rats after intraperitoneal injection of kynurenine and its metabolites. Pharmacol Res Comm 1978; 10: 81-4.
17. Lapin IP. Neurokynurenines (NEKY) as common neurochemical links of stress and anxiety. Adv Exp Med Biol 2003; 527: 121-25.
18. Oxenkrug GF, Lapin IP. Kynurenine pathway of the metabolism of tryptophan and its possible neuropharmacologic role. In: Yakovelev V (ed). Chemistry and pharmacology of indole compounds. Kishinev: Stinza, 1975.
19. Lapin IP. Antagonism of kynurenic acid to anxiogens in mice. Life Sci 1998; 63: 231-36.
20. Lapin IP. Kynurenines and anxiety. Adv Exp Med Biol 1996; 398: 191-94.
21. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002; 303: 1-10.
22. Hayaishi O. Properties and function of indoleamine 2, 3-dioxygenase. J Biochem 1976; 79: 13-21.
23. Gál EM, Sherman AD. L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 1980; 5: 223-39.
24. Kopin IJ, Pare CB, Axelrod J, Weissbach H. The fate of melatonin in animals. J Biol Chem 1961; 236: 3072-5.
25. Walsh HA, Daya S. Inhibition of hepatic tryptophan-2, 3-dioxygenase: superior potency of melatonin over serotonin. J Pineal Res 1997; 23: 20-3.
26. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science 1980; 210: 1267-69.
27. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9: 41-50.
28. Oxenkrug GF, Requintina PJ. Melatonin and jet lag syndrome: experimental model and clinical implications. CNS Spectrums 2003; 8: 139-48.
29. Oxenkrug GF. Genetic and hormonal regulation of the kynurenine pathway of tryptophan metabolism: new target for clinical intervention in vascular dementia, depression and aging. Ann NY Acad Sci 2007; 1122: 35-49.
30. Guidetti P, Amori L, Sapko MT, Okuno E, Schwarcz R. Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem 2007; 102: 10311.
31. Zarate CA, Jr Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57: 430-2.
32. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
33. Zawilska JB, Rosiak J, Senderecka M, Nowak JZ. Suppressive effect of NMDA receptor antagonist MK-801 on nocturnal serotonin N-acetyltransferase activity in the rat pineal gland. Pol J Pharmacol 1997; 49: 479-83.
34. Müller N, Schwarz M. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: Schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci 2008; 258: 97-106.
35. Oxenkrug GF. Tryptophan metabolism as a new target for the treatment of schizophrenia. US Psychiatry Review 2007: 38-9.
36. Oxenkrug GF. Antioxidant effects of N-acetylserotonin: possible mechanisms and clinical implications. Ann NY Acad Sci 2005; 1053: 334-47.
37. Melillo G, Cox DW, Biragyn A, Sheffler LA, Varesio L. Regulation of nitric-oxide synthase mRNA expression by interferongamma and picolinic acid. J Biol Chem 1994; 269: 8128-33.
38. Schwieler L, Erhardt S, Nilsson L, Linderholm K, Engberg G. Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons: possible involvement of endogenous kynurenic acid. Synapse 2006; 59: 290-8.
39. Manev G, Manev R. 5-lipoxygenase as a possible biological link between depressive symptoms and atherosclerosis. Arch Gen Psychiatry 2007; 64: 1333.
40. Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders and dysregulation of tryptophan-kynurenine pathway metabolism. Ann NY Acad Sci 2010; 1199: 1-14.
41. Oxenkrug GF. Antidepressant effect of N-acetylserotonin in relation to aging, hypertension and cancer. In: Berstein L (ed). Hormones, age and cancer. St. Petersburg: Nauka, 2005.
42. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alphabased immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90.
43. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M. IDO and interferon-alpha induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatr 2005; 10: 538-44.
44. Maes M, Capuron L, Ravaud A, et al. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacol 2001; 24: 130-40.
45. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002; 303: 1-10.
46. Borland LM, Michael AC. Voltammetric study of the control of striatal dopamine release by glutamate. J Neurochem 2004; 91: 220-9.
47. Khaspekov L, Kida E, Victorov I, Mossakowski MJ. Neurotoxic effect induced by quinolinic acid in dissociated cell culture of mouse hippocampus. J Neurosci Res 1989; 22: 150-7.
48. Pemberton LA, Kerr SJ, Smythe G, Brew BJ. Quinolinic acid production by macrophages stimulated with IFNγ, TNF-alpha, and IFNa. J Interf Cytokine Res 1997; 17: 589-95.
49. Kerr SJ, Armati PJ, Guillemin GJ, Brew BJ. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 1998; 12: 355-63.
50. Levivier M, Przedborski S. Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment. Neurol Res 1998; 20: 46-56.
51. Stone TW, Behan WM. Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist. J Neurosci Res 2007; 85: 1077-85.
52. Rios C, Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 1991; 16: 1139-43.
53. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002; 303: 1-10.
54. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007; 12: 988-1000.
55. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008; 13: 501-10.
56. Forrest CM, Mackay GM, Stoy N, Forrest CM. Tryptophan loading induces oxidative stress. Free Radic Res 2004; 38: 1167-71.
57. Maes M, Meltzer HY, Scharpe S, et al. Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatr Res 1993; 49: 151-65.
58. Maes M, Scharpe S, Meltzer H, et al. Increased neopterin and interferon gamma secretion and lower L-tryptophan levels in major depression: further evidence for immune activation in severe depression. Psychiatr Res 1994; 54: 143-60.
59. Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 2000; 12: 588-94.
60. Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 2007; 28: 826-31.
61. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237-41.
62. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M. IDO and interferon-alpha induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatr 2005; 10: 538-44.
63. O'Connor JC, Lawson MA, André C, et al. Lipopolysaccharideinduced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice. Mol Psychiatry 2009; 14: 511-22.
64. Rubin RT. Adrenal cortical activity changes in manic-depressive illness. Influence on intermediary metabolism of tryptophan. Arch Gen Psychiatry 1967; 17: 671-9.
65. Bender DA, Laing AE, Vale JA, Papadaki L, Pugh M. The effects of oestrogen administration on tryptophan metabolism in rats and in menopausal women receiving hormone replacement therapy. Biochem Pharmacol 1983; 32: 843-8.
66. Shibata K, Toda S. Effects of sex hormones on the metabolism of tryptophan to niacin and to serotonin in male rats. Biosci Biotechnol Biochem 1997; 61: 1200-2.
67. Taylor MW, Feng GS. Relationship between interferongamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5: 2516-22.
68. Widner B, Ledochowski M, Fuchs D. Interferon-gamma-induced tryptophan degradation: Neuropsychiatric and immunological consequences. Curr Drug Metab 2000; 1: 193-204.
69. Alberati-Giani D, Ricciardi-Castagnoli P, Köhler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem 1996; 66: 996-1004.
70. Sweeten TL, Ferris M, McDougle CJ, Kwo P, Taylor MW. Induction of indoleamine 2, 3-dioxygenase in vivo by IFN-con1. J Interferon Cytokine Res 2001; 21: 631-3.
71. Taylor JL, Grossberg SE. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol 1998; 25: 23-9.
72. Capuron L, Miller AH. Cytokines and psychopathology: Lessons from interferon-alpha. Biol Psychiatry 2004; 56: 819-24.
73. Bonaccorso S, Meltzer HY, Maes M. Psychological and behavioral effects of interferons. Curr Opin Psychiatry 2000; 13: 673-7.
74. Robinson CM, Hale PT, Carlin JM. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 2005; 25: 20-30.
75. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor-alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177: 557-60.
76. Liebau C, Baltzer AW, Schmidt S, et al. Interleukin-12 and interleukin-18 induce indoleamine 2, 3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res 2002; 22: 931-36.
77. Kwidzinski E, Bunse J, Aktas O, et al. Indolamine 2, 3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 2005; 19: 1347-9.
78. O'Connor JC, André C, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2, 3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009; 29: 4200-9.
79. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human INFG gene: Absolute correlation with a polymorphic CA micro marker of high INFG gene. Hum Immunol 2000; 61: 8333-66.
80. Anuradha B, Rakh SS, Ishaq M, eMurthy KJ, Valluri VL. Interferon-gamma Low producer genotype +874 overrepresented in Bacillus Calmette-Guerin nonresponding children. Pediatr Infect Dis J 2008; 27: 325-9.
81. Raitala A, Pertovaara M, Karjalainen J, Oja SS, Hurme M. Association of interferon-gamma+874(T/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals. Scand J Immunol 2005; 61: 387-90.
82. Jun TY, Pae CU, Hoon-Han, et al. Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet 2003; 13: 179-81.
83. Pae CU, Lee KU, Han H, Serretti A, Jun TY. Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. Psychiatry Res 2004; 125: 65-8.
84. Czerski PM, Rybakowski F, Kapelski P, et al. Association of tumor necrosis factor -308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology 2008; 57: 88-94.
85. Kawaguchi R, Ozawa-Kondo M, Ohta-Misaki I, et al. Prolactin (PRL) up-regulates indoleamine 2, 3-dioxygenase (IDO) expression in CD14+ cells. Nihon Rinsho Meneki Gakkai Kaishi 2005; 228: 407-12.
86. Fox HS, Bond BL, Parslow TG. Estrogen regulates the IFNgamma promoter. J Immunol 1991; 146: 4362-7.
87. Ozaki Y, Edelstein MP, Duch DS. The actions of interferon and antiinflammatory agents of induction of indoleamine 2, 3-dioxygenase in human peripheral blood monocytes. Biochem Biophys Res Commun 1987; 144: 1147-53.
88. Coryell W, Fiedorowicz J, Zimmerman M, Young E. HPA-axis hyperactivity and mortality in psychotic depressive disorder: preliminary findings. Psychoneuroendocrinol 2008; 33: 654-8.
89. Carroll BJ, Feinberg M, Greden JF, et al. Diagnosis of endogenous depression. Comparison of clinical, research and neuroendocrine criteria. J Affect Disord 1980; 2: 177-94.
90. Brown WA, Shuey I. Response to dexamethasone and subtype of depression. Arch Gen Psychiatry 1980; 37: 747-51.
91. Mendlewicz J, Charles G, Franckson JM. The dexamethasone suppression test in affective disorder: relationship to clinical and genetic subgroups. Br J Psychiatry 1982; 141: 464-70.
92. Evans DL, Nemeroff CB. The clinical use of the dexamethasone suppression test in DSM-III affective disorders: correlation with the severe depressive subtypes of melancholia and psychosis. J Psychiatr Res 1987; 21: 185-94.
93. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997; 154: 1497-503.
94. Maes M, Bosmans E, Meltzer HY, Scharpre S, Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993; 150: 1189-93.
95. Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: Facts and hypotheses. Endocr Rev 1996; 17: 64-102.
96. Miller AH, Maletic V, Raison CL. Inflammation and its discontents; the role of cytokines in the pathophysiology of Major Depression. Biol Psych 2009; 65: 732-41.
97. Cassidy EM, Manning D, Byrne S, et al. Acute effects of lowdose interferon-alpha on serum cortisol and plasma interleukin-6. J Psychopharmacol 2002; 16: 230-4.
98. Soygur H, Palaoglu O, Akarsu ES, et al. Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psych 2007; 31: 1242-7.
99. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 160: 1342-5.
100. Pariante CM, Nemeroff CB, Miller AH. Glucocorticoid receptors in depression. Isr J Med Sci 1995; 31: 705-12.
101. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391-404.
102. Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007; 21: 9-19.
103. Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 2009; 1179: 86-105.
104. Mazzeo RS, Donovan D, Fleshner M, et al. Interleukin-6 response to exercise and high-altitude exposure: influence of alpha-adrenergic blockade. J Appl Physiol 2001; 91: 2143-9.
105. Johnson JD, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neurosci 2005; 135: 1295-307.
106. Campbell S, MacQueen G. An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry 2006: 19: 25-33.
107. Dilman VM, Lapin IP, Oxenkrug GF. Serotonin and aging. In: Essman W (ed). Serotonin in health and disease. New York, London: Spectrum, 1979.
108. Oxenkrug GF, McIntyre IM, Stanley M, Gershon S. Dexamethasone suppression test: experimental model in rats and effect of age. Biol Psychiat 1984; 19: 413-16.
109. Oxenkrug GF, Pomara N, McIntyre I, Branconnier RJ, Stanley M, Gershon S. Aging and cortisol resistance to suppression by dexamethasone: a positive correlation. Psychiatry Res 1983; 10: 125-30.
110. Rodríguez MI, Escames G, López LC, et al. Chronic melatonin treatment reduces the age-dependent inflammatory process in senescence-accelerated mice. J Pineal Res 2007; 42: 272-9.
111. Pertovaara M, Raitala A, Lehtimaki T, et al. Indoleamine 2, 3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality. Mech Ageing Dev 2006; 127: 497-9.
112. Oxenkrug GF. The extended life span of Drosophila melanogaster eye-color (white and vermilion) mutants with impaired formation of kynurenine. J Neural Transm 2010; 117: 23-6.
113. Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 1998; 172: 527-32.
114. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-13.
115. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998; 9: 2023-28.
116. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999; 19: 5034-43.
117. MacQueen GM, Campbell S, McEwen BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 2003; 100: 1387-92.
118. Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry 2000; 48: 791-800.
119. Sheline YI. Neuroimaging studies of mood disorder: effects on the brain. Biol Psychiatry 2003; 54: 338-52.
120. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004; 5: 11-25.
121. Sapolsky RM. Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry 2004; 56: 137-9.
122. Duman RS, Malberg J, Nakagawa S. Regulation of adult neurogenesis by psychotropic drugs and stress. J Pharmacol Exp Ther 2001; 99: 401-7.
123. Cameron HA, Gould E. Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience 1994; 61: 203-9.
124. Gould E, McEwen BS, Tanapat P, Galea LA, Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci 1997; 17: 2492-8.
125. Mirescu C, Peters JD, Gould E. Early life experience alters response of adult neurogenesis to stress. Nat Neurosci 2004; 7: 841-6.
126. Malberg JE, Eisch AJ, Nestler EJ, Duman RS, . Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
127. Bjornebekk A, Mathe AA, Brene S. The antidepressant effect of running is associated with increased hippocampal cell proliferation. Int J Neuropsychopharmacol 2005; 8: 357-68.
128. Zou JY, Crews FT. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 2005; 1034: 11-24.
129. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1545-64.
130. Chaldakov GN, Tonchev AB, Aloe L. NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines. Riv Psichiatr 2009: 44: 79-87.
131. Horch HW, Katz LC. BDNF release from single cells elicits local dendritic growth in nearby neurons. Nat Neurosci 2002; 5: 1177-84.
132. Lee J, Duan W, Mattson MP. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem 2002; 82: 1367-75.
133. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57: 1068-72.
134. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328: 261-4.
135. Gonul AS, Akdenz F, Taneli DO, Eker C, Vahip S. The effect of treatment on serum brain-derived neurotrophic factor in depressed patients. Eur Neuropsychopharmacol 2003; 13: S203.
136. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54: 70-5.
137. Gervasoni N, Aubry JM, Bondolfi G, et al. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiol 2005; 51: 234-8.
138. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Progr Neuropsychopharm Biol Psychiatry 2005; 29: 261-5.
139. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in post-mortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Molec Brain Research 2005; 136: 29-37.
140. Lang UE, Hellweg R, Gallinat J. BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacol 2004; 29: 795-8.
141. Piccinni A, Marazziti D, Catena M, et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Dis 2008; 105: 279-83.
142. Catena Dell'Osso M, Piccinni A, Faravelli L, Massimetti G, Marazziti D. Drug-free depressed patients show decreased plasma and serum brain-derived neurotrophic factor (BDNF) levels. Clinical Neuropsychiatry 2007; 4: 122-6.
143. Goshen I, Kreisel T, Ben-Menachem-Zidon O, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008; 13: 717-28.
144. Bernardino L, Agasse F, Silva B, Ferreira R, Grade S, Malva JO. Tumor necrosis factor-alpha modulates survival, proliferation, and neuronal differentiation in neonatal subventricular zone cell cultures. Stem Cells 2008; 26: 2361-71.
145. Schulte-Herbruggen O, Nassenstein, C, Lommatzsch M, Quarcoo D, Renz H, Braun A. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol 2005; 160: 204-9.
146. Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 2008; 105: 751-6.
147. Ben Menachem-Zidon O, Goshen I, Kreisel T, et al. Intrahippocampal transplantation of transgenic neural precursor cells overexpressing interleukin-1 receptor antagonist blocks chronic isolation-induced impairment in memory and neurogenesis. Neuropsychopharm 2008; 33: 2251-62.
148. Barrientos RM, Sprunger DB, Campeau S, et al. Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neuroscience 2003; 121: 847-53.
149. Wu CW, Chen YC, Yu L, et al. Treadmill exercise counteracts the suppressive effects of peripheral lipopolysaccharide on hippocampal neurogenesis and learning and memory. J Neurochem 2007; 103: 2471-81.
150. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glia cells. Biol Psychiatry 2000; 48: 766-77.
151. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Research Rev 2004; 45: 104-14.
152. Levinson DF. The genetics of depression: a review. Biol Psychiatry 2006; 60: 84-92.
153. Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biol Psychiatry 2006; 59: 1116-27.
154. Alfarez DN, Joëls M, Krugers HJ. Chronic unpredictable stress impairs long-term potentiation in rat hippocampal CA1 area and dentate gyrus in vitro. Eur J Neurosci 2003; 17: 1928-34.
155. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatr Res 1999; 85: 275-91.
156. Beltz BS, Tlusty MF, Benton JL, Sandeman DC. Omega-3 fatty acids upregulate adult neurogenesis. Neurosci Lett 2007; 145: 154-8.